title: Topiramate: effects on serum lipids and lipoproteins levels in children.
abstract: The present controlled study aims to evaluate topiramate (TPM) effect on total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein, very low-density lipoprotein, apolipoproteins A1, B and lipoprotein (a). Seventy patients in evolving age suffering from various types of epilepsy, treated with TPM, (age range: 6 months-22 years) were evaluated before and after 12 months of treatment and compared with 110 sex- and age-matched subjects. At baseline, no significant difference was present between controls and children treated with TPM. After a year, the BMI did not show significant change in adults and remained into respective growth curve. No significant difference in lipids and lipoproteins neither between first and second evaluation nor between patients and controls was found. Some intra-group variation has been noticed: whilst controls maintained similar levels, the 70 patients on TPM monotherapy showed a slight decrease in TC, triglycerides and HDL. These fluctuations, however, occurred in the normal range so neither dietary nor pharmacological treatment of hyperlipidaemia after a year of TPM was necessary.
authors.affiliation: Child Neuropsychiatry Unit, University of Bologna, Bologna, Italy. emailio.franzoni@unibo.it
authors.forename: E
authors.initials: E
authors.lastname: Franzoni
authors.forename: A
authors.initials: A
authors.lastname: Verrotti
authors.forename: J
authors.initials: J
authors.lastname: Sarajlija
authors.forename: C
authors.initials: C
authors.lastname: Garone
authors.forename: S
authors.initials: S
authors.lastname: Matricardi
authors.forename: G G
authors.initials: GG
authors.lastname: Salerno
authors.forename: M
authors.initials: M
authors.lastname: Monti
authors.forename: F
authors.initials: F
authors.lastname: Chiarelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D001053:Apolipoproteins / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007223:Infant; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D011446:Prospective Studies; D013995:Time; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D001053:Apolipoproteins; D008055:Lipids; D017270:Lipoprotein(a); D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D000077236:Topiramate; D005632:Fructose; D002784:Cholesterol